Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities

Core Insights - Day One Biopharmaceuticals reported preliminary unaudited net product revenue of approximately $57.2 million for 2024, with $29.0 million generated in the fourth quarter alone [2][3] - The company ended 2024 with approximately $531.7 million in cash, cash equivalents, and short-term investments, a significant increase from $366.3 million at the end of 2023 [3] - OJEMDA received FDA accelerated approval in April 2024, becoming the first FDA-approved therapy for pediatric low-grade glioma [6] Financial Highlights - Preliminary 2024 OJEMDA net product revenue was approximately $57.2 million, with $29.0 million in the fourth quarter [2][7] - Cash, cash equivalents, and short-term investments totaled approximately $531.7 million as of December 31, 2024, compared to $366.3 million on December 31, 2023 [3] Business Updates - The company aims to drive OJEMDA revenue and invest in programs leveraging its expertise in development and commercialization [2] - Enrollment in the pivotal Phase 3 FIREFLY-2 clinical trial for tovorafenib is expected to be completed in the first half of 2026 [6] - Day One has expanded its pipeline with the in-licensing of DAY301 and has cleared the first cohort in the Phase 1a portion of the DAY301 Phase 1a/b clinical trial [6] Upcoming Priorities - The company plans to continue growing OJEMDA revenue and advancing its existing pipeline, including the FIREFLY-2 Phase 3 clinical trial and DAY301 [6] - Day One will pursue business development opportunities to expand its pipeline while maintaining a self-sustaining financial position [6]